Danny Sheng Wu Yeung Buys 7,500 Shares of Prenetics Global (NASDAQ:PRE) Stock

Prenetics Global Limited (NASDAQ:PREGet Free Report) CEO Danny Sheng Wu Yeung purchased 7,500 shares of Prenetics Global stock in a transaction dated Thursday, August 20th. The shares were acquired at an average cost of $18.31 per share, with a total value of $137,325.00. Following the transaction, the chief executive officer directly owned 95,235 shares in the company, valued at approximately $1,743,752.85. The trade was a 8.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Danny Sheng Wu Yeung also recently made the following trade(s):

  • On Monday, August 24th, Danny Sheng Wu Yeung acquired 17,181 shares of Prenetics Global stock. The stock was acquired at an average price of $21.23 per share, for a total transaction of $364,752.63.

Prenetics Global Trading Up 6.6%

PRE opened at $23.25 on Wednesday. The company’s 50 day moving average is $19.12 and its 200 day moving average is $18.93. The company has a market cap of $392.23 million, a price-to-earnings ratio of -5.59 and a beta of 0.26. Prenetics Global Limited has a 12-month low of $7.25 and a 12-month high of $23.63.

Prenetics Global (NASDAQ:PREGet Free Report) last announced its earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.31. The business had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. As a group, analysts predict that Prenetics Global Limited will post -1.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PRE has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Wall Street Zen upgraded Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Benchmark raised their price objective on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Prenetics Global has a consensus rating of “Moderate Buy” and an average price target of $34.25.

View Our Latest Stock Analysis on PRE

Institutional Trading of Prenetics Global

Hedge funds have recently modified their holdings of the company. State of Wyoming bought a new stake in shares of Prenetics Global in the 1st quarter valued at approximately $48,000. Wells Fargo & Company MN bought a new position in shares of Prenetics Global during the 4th quarter valued at approximately $47,000. JPMorgan Chase & Co. purchased a new stake in Prenetics Global during the 3rd quarter valued at $65,000. Operose Advisors LLC purchased a new stake in Prenetics Global during the 2nd quarter valued at $129,000. Finally, Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the fourth quarter worth $170,000. 25.01% of the stock is owned by hedge funds and other institutional investors.

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

Featured Stories

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.